BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
3/19/2026 7:07:29 AM | Browse: 36 | Download: 74
 |
Received |
|
2025-11-25 03:25 |
|
Peer-Review Started |
|
2025-11-25 03:26 |
|
First Decision by Editorial Office Director |
|
2025-12-16 09:59 |
|
Return for Revision |
|
2025-12-16 09:59 |
|
Revised |
|
2025-12-29 02:10 |
 |
Publication Fee Transferred |
|
|
|
Second Decision by Editor |
|
2026-01-09 02:36 |
|
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2026-01-09 09:55 |
|
Articles in Press |
|
2026-01-09 09:55 |
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2026-02-28 07:59 |
|
Publish the Manuscript Online |
|
2026-03-19 07:07 |
| ISSN |
1007-9327 (print) and 2219-2840 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Editorial |
| Article Title |
From clinical efficacy to population health: Implementing vonoprazan-amoxicillin dual therapy for Helicobacter pylori control
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Qing Chen, Kang-Ning Li and Tian-Qi Liu |
| ORCID |
|
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| Medical and Health Appropriate Technology Development and Promotion Project of the Health Commission of Guangxi Zhuang Autonomous Region |
No. S2023034 |
|
| Corresponding Author |
Tian-Qi Liu, Consultant, MD, PhD, Professor, Department of General Surgery, Jiangbin Hospital of Guangxi Zhuang Autonomous Region, No. 85 Hedi Road, Nanning 530021, Guangxi Zhuang Autonomous Region, China. ljrqt@126.com |
| Key Words |
Helicobacter pylori; Vonoprazan; Amoxicillin; Dual therapy; Eradication treatment; Public health; Pharmacoeconomics; Antibiotic resistance |
| Core Tip |
This editorial highlights vonoprazan-amoxicillin dual therapy, particularly the 0.5 g four-times-daily regimen, as a highly effective, safe, and well-tolerated strategy for Helicobacter pylori eradication, based on a recent large-scale regional trial. Its exceptional cost-effectiveness, high patient compliance, and dosing simplicity position it as a transformative candidate for large-scale public health interventions that aimed at reducing the burden of Helicobacter pylori-associated diseases, including gastric cancer. Successful implementation, however, necessitates addressing challenges such as antimicrobial resistance surveillance and ensuring equitable access to healthcare systems. |
| Publish Date |
2026-03-19 07:07 |
| Citation |
Chen Q, Li KN, Liu TQ. From clinical efficacy to population health: Implementing vonoprazan-amoxicillin dual therapy for Helicobacter pylori control. World J Gastroenterol 2026; 32(12): 116953 |
| URL |
https://www.wjgnet.com/1007-9327/full/v32/i12/116953.htm |
| DOI |
https://dx.doi.org/10.3748/wjg.v32.i12.116953 |
All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.
